Antibiotic resistance has emerged as one of the gravest global health challenges of the 21st century, undermining the effectiveness of available treatments ...

BOSTON, Sept. 15, 2025) ("Tiziana" or the "Company"), a biotechnology company developing breakthrough immunomodulation therapies with its lead development candidate, intranasal foralumab, a fully huma ...

INmune Bio Inc. (NASDAQ: INMB) ("INmune" or "the Company"), a clinical-stage inflammation and immunology company focused on developing treatments ...